Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Exclusion criteria

• . Squamous cell or undifferentiated gastric cancer.
• . Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• . Subjects with an active, known or suspected autoimmune disease. Patients with type I diabetes who are receiving a stable dose of insulin, hypothyroidism who only needs hormone replacement therapy, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and do not have acute deterioration within 1 year before the screening period, are allowed.
• . Clinically significant cardiovascular and cerebrovascular diseases.
• . Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs.
• . Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency.
• . Arterial / venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, occurred within the first 6 months of randomization.
• . Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.